FR13C0044I1 - - Google Patents

Info

Publication number
FR13C0044I1
FR13C0044I1 FR13C0044C FR13C0044I1 FR 13C0044 I1 FR13C0044 I1 FR 13C0044I1 FR 13C0044 C FR13C0044 C FR 13C0044C FR 13C0044 I1 FR13C0044 I1 FR 13C0044I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR13C0044I1 publication Critical patent/FR13C0044I1/fr
Application granted granted Critical
Publication of FR13C0044I2 publication Critical patent/FR13C0044I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR13C0044C 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine Active FR13C0044I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41759002P 2002-10-10 2002-10-10
PCT/EP2003/011212 WO2004032938A1 (fr) 2002-10-10 2003-10-09 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine

Publications (2)

Publication Number Publication Date
FR13C0044I1 true FR13C0044I1 (fr) 2013-08-30
FR13C0044I2 FR13C0044I2 (fr) 2014-03-07

Family

ID=32094042

Family Applications (2)

Application Number Title Priority Date Filing Date
FR13C0044C Active FR13C0044I2 (fr) 2002-10-10 2013-07-24 Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR22C1033C Active FR22C1033I1 (fr) 2002-10-10 2022-06-30 Utilisation de dihydroimidazolones pour le traitement des chiens

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR22C1033C Active FR22C1033I1 (fr) 2002-10-10 2022-06-30 Utilisation de dihydroimidazolones pour le traitement des chiens

Country Status (28)

Country Link
US (5) US20050070537A1 (fr)
EP (3) EP2845594B1 (fr)
JP (4) JP4694202B2 (fr)
KR (2) KR20110063843A (fr)
CN (2) CN1726040B (fr)
AR (1) AR041573A1 (fr)
AT (1) ATE418337T1 (fr)
AU (2) AU2003273978B2 (fr)
BE (1) BE2013C046I2 (fr)
BR (1) BR0315225A (fr)
CA (2) CA2727722C (fr)
CY (3) CY1109961T1 (fr)
DE (1) DE60325496D1 (fr)
DK (2) DK2845594T3 (fr)
ES (2) ES2908453T3 (fr)
FR (2) FR13C0044I2 (fr)
HK (1) HK1085920A1 (fr)
HR (3) HRP20090667B1 (fr)
HU (2) HUS1300035I1 (fr)
LU (1) LU92238I2 (fr)
MX (1) MXPA05003663A (fr)
NZ (1) NZ539864A (fr)
PL (2) PL214702B1 (fr)
PT (2) PT1553952E (fr)
SI (2) SI1553952T1 (fr)
TW (2) TWI324067B (fr)
WO (1) WO2004032938A1 (fr)
ZA (1) ZA200502245B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050070537A1 (en) * 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
MXPA05013196A (es) * 2003-07-11 2006-03-09 Elbion Ag Metodo para tratar o evitar trastornos del sistema nervioso central con compuestos que tienen selectividad por la subunidad alfa 3 del receptor de benzodiazepina.
RU2014109074A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
JP6193613B2 (ja) * 2013-05-10 2017-09-06 学校法人麻布獣医学園 てんかん発作のモニタリングシステム及びモニタリング方法
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals
US9856250B2 (en) 2014-05-28 2018-01-02 Toa Eiyo Ltd. Substituted tropane derivatives
US10117891B2 (en) 2014-09-16 2018-11-06 India Globalization Capital, Inc. Cannabinoid composition for treating pain
EP3247359A4 (fr) 2015-01-25 2018-08-08 India Globalization Capital, Inc. Compositions et procédés de traitement de troubles épileptiques
US10596159B2 (en) 2015-08-12 2020-03-24 India Globalization Capital, Inc. Method and composition for treating cachexia and eating disorders
WO2017218629A1 (fr) 2016-06-15 2017-12-21 India Globalization Capital, Inc. Méthode et composition pour traiter des troubles epileptiques

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4044021A (en) 1971-10-21 1977-08-23 American Cyanamid Company Tetrasubstituted imidazolidine diuretics useful in the treatment of hyperaldosteronism
US3932452A (en) 1975-02-07 1976-01-13 Morton-Norwich Products, Inc. 1-Arylmethyl-2-imidazolidinones
DE19532668A1 (de) 1995-09-05 1997-03-06 Dresden Arzneimittel Neue, antikonvulsiv wirkende 1-Ar(alk)yl-imidazolin-2-one, die in 4-Stellung einen disubstituierten Amin-Rest enthalten, und Verfahren zu deren Herstellung
US5869481A (en) 1995-09-05 1999-02-09 Arzneitmittelwerk Dresden G.M.B.H. Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
DE19721580A1 (de) * 1997-05-23 1998-11-26 Dresden Arzneimittel Verwendung von 1-Ar(alk)yl-imidazolin-2-one zur Behandlung von Angst- und Spannungszuständen
AU8168998A (en) * 1997-06-26 1999-01-19 Board Of Regents, The University Of Texas System Synthesis of dihydrohonokiol compositions
JP4669095B2 (ja) * 1999-07-19 2011-04-13 太陽化学株式会社 ペットの問題行動抑制組成物
EA009664B1 (ru) 2002-03-07 2008-02-28 Бёрингер Ингельхайм Фарма Гмбх Унд Ко. Кг Предназначенная для перорального применения лекарственная форма для этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его солей
US20050070537A1 (en) 2002-10-10 2005-03-31 Chris Rundfeldt Use of dihydroimidazolones for the treatment of dogs
DE10339862A1 (de) 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
RU2014109074A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх ИНГИБИТОРЫ ФАННИ-ТОКА (If), ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ЛЕЧЕНИЯ И ПРЕДУПРЕЖДЕНИЯ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У КОШАЧЬИХ
US9820988B2 (en) 2014-03-24 2017-11-21 Boehringer Ingelheim Vetmedica Gmbh Treatment of epileptic disorders in feline animals

Also Published As

Publication number Publication date
SI1553952T1 (sl) 2009-04-30
BE2013C046I2 (fr) 2022-08-09
US20130065898A1 (en) 2013-03-14
LU92238I2 (fr) 2013-09-03
JP2011068685A (ja) 2011-04-07
JP2006503873A (ja) 2006-02-02
EP2845594A1 (fr) 2015-03-11
CN1726040B (zh) 2010-05-12
AU2009225322A1 (en) 2009-11-05
DK1553952T3 (da) 2009-04-20
CA2501772A1 (fr) 2004-04-22
PL397320A1 (pl) 2012-02-13
FR22C1033I1 (fr) 2022-09-09
DK2845594T3 (da) 2022-03-07
CY1125103T1 (el) 2023-01-05
HRP20050322A2 (en) 2006-05-31
HUS1300035I1 (hu) 2017-10-30
CY2013031I2 (el) 2015-11-04
EP1553952A1 (fr) 2005-07-20
DE60325496D1 (de) 2009-02-05
TW200503726A (en) 2005-02-01
HRP20050322B1 (hr) 2013-12-06
US8859540B2 (en) 2014-10-14
CA2727722A1 (fr) 2004-04-22
HK1085920A1 (en) 2006-09-08
CA2501772C (fr) 2011-08-23
PT2845594T (pt) 2022-03-09
US20160367562A1 (en) 2016-12-22
LU92238I9 (fr) 2019-01-09
PT1553952E (pt) 2009-02-10
ZA200502245B (en) 2005-11-30
TW201010706A (en) 2010-03-16
CY1109961T1 (el) 2014-09-10
AR041573A1 (es) 2005-05-18
HUS2200036I1 (hu) 2022-08-28
JP4694202B2 (ja) 2011-06-08
PL374603A1 (en) 2005-10-31
ATE418337T1 (de) 2009-01-15
CA2727722C (fr) 2013-05-28
ES2908453T3 (es) 2022-04-29
AU2003273978A1 (en) 2004-05-04
JP2014080449A (ja) 2014-05-08
BR0315225A (pt) 2005-08-23
CN1726040A (zh) 2006-01-25
TWI324067B (en) 2010-05-01
AU2003273978B2 (en) 2009-07-23
EP2845594B1 (fr) 2022-02-23
HRP20090667A2 (hr) 2010-07-31
US20150072983A1 (en) 2015-03-12
KR20050056237A (ko) 2005-06-14
KR101110587B1 (ko) 2012-02-15
CY2013031I1 (el) 2015-11-04
FR13C0044I2 (fr) 2014-03-07
JP6249812B2 (ja) 2017-12-20
US9469611B2 (en) 2016-10-18
PL214702B1 (pl) 2013-09-30
JP2016104817A (ja) 2016-06-09
US20080027057A1 (en) 2008-01-31
CN101890019A (zh) 2010-11-24
HRP20200207A2 (hr) 2020-07-24
EP2036563A1 (fr) 2009-03-18
NZ539864A (en) 2007-11-30
TWI424849B (zh) 2014-02-01
SI2845594T1 (sl) 2022-04-29
WO2004032938A1 (fr) 2004-04-22
KR20110063843A (ko) 2011-06-14
ES2316808T3 (es) 2009-04-16
HRP20090667B1 (hr) 2021-06-11
EP1553952B1 (fr) 2008-12-24
US8962617B2 (en) 2015-02-24
US20050070537A1 (en) 2005-03-31
PL238776B1 (pl) 2021-10-04
MXPA05003663A (es) 2005-06-08

Similar Documents

Publication Publication Date Title
BE2017C049I2 (fr)
BE2016C040I2 (fr)
BE2016C013I2 (fr)
BE2016C002I2 (fr)
BE2015C078I2 (fr)
BE2015C017I2 (fr)
BE2014C053I2 (fr)
BE2014C051I2 (fr)
BE2014C041I2 (fr)
BE2014C030I2 (fr)
BE2014C016I2 (fr)
BE2014C015I2 (fr)
BE2013C063I2 (fr)
BE2013C039I2 (fr)
BE2011C038I2 (fr)
ECSDI024330S (fr)
BRPI0302144B1 (fr)
FR13C0044I1 (fr)
JP2003102702A5 (fr)
JP2002320034A5 (fr)
JP2003204472A5 (fr)
JP2003206402A5 (fr)
JP2003188147A5 (fr)
JP2003205156A5 (fr)
JP2003205155A5 (fr)